Muhammad Naveed, Shamsa Mubeen, Abeer Khan, Sehrish Ibrahim, Bisma Meer
{"title":"Plasma Biomarkers: Potent Screeners of Alzheimer's Disease.","authors":"Muhammad Naveed, Shamsa Mubeen, Abeer Khan, Sehrish Ibrahim, Bisma Meer","doi":"10.1177/1533317519848239","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD), a neurological disorder, is as a complex chronic disease of brain cell death that usher to cognitive decline and loss of memory. Its prevalence differs according to risk factors associated with it and necropsy performs vital role in its definite diagnosis. The stages of AD vary from preclinical to severe that proceeds to death of patient with no availability of treatment. Biomarker may be a biochemical change that can be recognized by different emerging technologies such as proteomics and metabolomics. Plasma biomarkers, 5-protein classifiers, are readily being used for the diagnosis of AD and can also predict its progression with a great accuracy, specificity, and sensitivity. In this review, upregulation or downregulation of few plasma proteins in patients with AD has also been discussed, when juxtaposed with control, and thus serves as potent biomarker in the diagnosis of AD.</p>","PeriodicalId":50816,"journal":{"name":"American Journal of Alzheimers Disease and Other Dementias","volume":"34 5","pages":"290-301"},"PeriodicalIF":2.7000,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10852434/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Alzheimers Disease and Other Dementias","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1533317519848239","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/5/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Alzheimer's disease (AD), a neurological disorder, is as a complex chronic disease of brain cell death that usher to cognitive decline and loss of memory. Its prevalence differs according to risk factors associated with it and necropsy performs vital role in its definite diagnosis. The stages of AD vary from preclinical to severe that proceeds to death of patient with no availability of treatment. Biomarker may be a biochemical change that can be recognized by different emerging technologies such as proteomics and metabolomics. Plasma biomarkers, 5-protein classifiers, are readily being used for the diagnosis of AD and can also predict its progression with a great accuracy, specificity, and sensitivity. In this review, upregulation or downregulation of few plasma proteins in patients with AD has also been discussed, when juxtaposed with control, and thus serves as potent biomarker in the diagnosis of AD.
阿尔茨海默病（AD）是一种神经系统疾病，是一种复杂的慢性脑细胞死亡疾病，会导致认知能力下降和记忆力丧失。其发病率因相关风险因素而异，尸体解剖在明确诊断中起着至关重要的作用。注意力缺失症分为不同阶段，从临床前期到严重阶段，在没有治疗方法的情况下会导致患者死亡。生物标志物可能是一种生化变化，可通过蛋白质组学和代谢组学等不同的新兴技术识别。血浆生物标志物--5种蛋白分类器--可随时用于诊断AD，并能预测其进展，具有极高的准确性、特异性和敏感性。在这篇综述中，还讨论了与对照组相比，AD 患者血浆中少数蛋白的上调或下调情况，这些蛋白可作为诊断 AD 的有效生物标志物。
期刊介绍：
American Journal of Alzheimer''s Disease and other Dementias® (AJADD) is for professionals on the frontlines of Alzheimer''s care, dementia, and clinical depression--especially physicians, nurses, psychiatrists, administrators, and other healthcare specialists who manage patients with dementias and their families. This journal is a member of the Committee on Publication Ethics (COPE).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
